Comparison 8. Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic venous thromboembolism	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Symptomatic pulmonary embolism	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3 Superficial thrombophlebitis progression into deep vein thrombosis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Major bleeding	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected